IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis
This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: • Mechanism of action for IL-31 inhibitor nemolizumab • Clinical safety and efficacy data for nemolizumab for treatment of PN • Strategies for prescribing IL-31 inhibitors in clinical practice • Pearls for patient selection and addressing treatment challenges
▶︎
Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis - Episode 1
▶︎
JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis
▶︎
DO THIS To Heal Your Psoriasis TODAY!
▶︎
Moving into the Non-Steroidal Topical Therapy Age
▶︎
The Insane Genius of a Formula 1 Gearbox
▶︎
MTHFR: The Root Cause of Fatigue That Doctors Call ‘Normal‘
▶︎
IDEF Educational Series The IL 31 Neuroimmune Pathway The Key to PN
▶︎
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?
▶︎
Itchy Bumps On The Skin | Prurigo Nodularis Explained
▶︎
Chronic Hand Eczema: All Hands on Deck
▶︎
Golden Retriever Meets Completely Broken Rescue for the First Time
▶︎
Was hilft bei Psoriasis? Bei Schuppenflechte juckt und brennt die Haut | Die Ernährungs-Docs | NDR
▶︎
Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management
▶︎
Voice of Customer Turning Physician Insight Into Action: Dr. Ira Kirschenbaum and Dr. A.J. Rush III
▶︎
Five Things Must Know for Nemluvio (Nemolizumab)!
▶︎
Doctor Reacts to Daricha's Prurigo Nodularis Journey
▶︎
Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?
▶︎
Nemluvio for Eczema: Is It Worth It? 🤔🧴
▶︎
A Dermatologist's Guide to Skin Growths | Dr. Sam Ellis
▶︎